Related Experiment Video
Updated: Jul 8, 2026
08:49
Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype
Published on: March 18, 2020
Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412
1Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, Dorothy Hodgkin Building, University of Bristol, Bristol, UK. colin.dayan@bris.ac.uk
Clinical and Experimental Immunology
|January 15, 2008
Summary
Immunotherapy research offers new treatments, but clinical trials for immune-targeting agents are complex. Immunologists play a vital role in advancing safe and effective immunotherapy development.
Area of Science:
- Immunology
- Translational Medicine
- Drug Development
Background:
- Current immunology research is yielding novel immunotherapy approaches.
- The TGN1412 clinical trial incident raised significant safety concerns for immune-targeting agents.
- Regulatory and industry stakeholders are cautious about new immunotherapies.
Purpose of the Study:
- To discuss the complexities of clinical trials involving immunotherapies.
- To highlight the essential role of immunologists in advancing immunotherapy research.
- To ensure the continued safe development of novel immunotherapies.
Main Methods:
- Literature review of current immunotherapy research.
- Analysis of the TGN1412 trial implications.
- Discussion of regulatory and industry perspectives on immunotherapies.
Main Results:
- The TGN1412 incident underscores the inherent risks in immunotherapy clinical trials.
- Complexities in immune system targeting require specialized expertise.
- A need for robust safety protocols in immunotherapy development is evident.
Conclusions:
- Immunologists are crucial for navigating the challenges in immunotherapy development.
- Continued progress in immunotherapy requires careful consideration of trial design and safety.
- Collaboration between researchers, regulators, and industry is key for advancing immunotherapies.
